Paper34636282
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy.
Sohail M and 4 others. Expert Rev Anticancer Ther, 2021. Cited by 77 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Papers, record 34636282. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34636282
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Neoplasms | Major topic |
| Cardiotoxicity | |
| Cell Line, Tumor | |
| Drug Delivery Systems | |
| Female | |
| Humans |
Source PubMed
Cited by49
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898624 | Bioengineering strategies to enhance BCG immunotherapy against bladder cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898624 | PubMed |
| 42460029 | Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma. | RSC Pharm | 2026 | https://conductscience.org/library/papers/42460029 | PubMed |
| 42215521 | Gold nanoparticles exhibit anticancer property through induction of oxidative stress and autophagy in MCF-7 breast cancer cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/42215521 | PubMed |
| 41896273 | A physics-informed machine learning framework for predicting and mitigating doxorubicin nanocarrier toxicity in normal cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/41896273 | PubMed |
| 41739691 | Linking Metabolomic Diversity to Pharmacological Potency in Anonidium mannii Leaf Extracts. | Chem Biodivers | 2026 | https://conductscience.org/library/papers/41739691 | PubMed |
| 41560793 | Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41560793 | PubMed |
| 41283276 | Breast Cancer Progression and Its Theranostic Management via Folate-Directed Targeting of Glycoprotein Receptor. | Med Sci (Basel) | 2025 | https://conductscience.org/library/papers/41283276 | PubMed |
| 41195221 | Effects of histidine and N-acetylcysteine on acute kidney injury induced by doxorubicin in rats: roles of anti-oxidative, anti-inflammatory and anti-apoptotic mechanisms. | Vet Res Forum | 2025 | https://conductscience.org/library/papers/41195221 | PubMed |
| 41153808 | Novel Cross-Cancer Hub Genes in Doxorubicin Resistance Identified by Transcriptional Mapping. | Biomedicines | 2025 | https://conductscience.org/library/papers/41153808 | PubMed |
| 41039183 | Anticancer compounds from Streptomyces: insights from metagenomics and mechanistic perspective. | Folia Microbiol (Praha) | 2025 | https://conductscience.org/library/papers/41039183 | PubMed |
| 41022604 | [Cinnamic acid ameliorates doxorubicin-induced myocardial injury in mice by attenuating cardiomyocyte ferroptosis via inhibiting TLR4]. | Nan Fang Yi Ke Da Xue Xue Bao | 2025 | https://conductscience.org/library/papers/41022604 | PubMed |
| 41011159 | A Systematic Review of Advances in Plant-Based Phospholipid Liposomes in Breast Cancer Therapy: Characterization, Innovations, Clinical Applications, and Future Directions. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41011159 | PubMed |
| 41008599 | The Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment. | Biomolecules | 2025 | https://conductscience.org/library/papers/41008599 | PubMed |
| 40789868 | Dichloroacetate enhances Chemo-sensitivity in wild-type P53 breast cancer cells by modulating ABCG2 and NKG2DL. | Sci Rep | 2025 | https://conductscience.org/library/papers/40789868 | PubMed |
| 40764352 | Abacavir enhances the efficacy of doxorubicin via inhibition of histone demethylase KDM5B in breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40764352 | PubMed |
| 40492153 | CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40492153 | PubMed |
| 40281790 | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy. | Bioengineering (Basel) | 2025 | https://conductscience.org/library/papers/40281790 | PubMed |
| 40277662 | Temperature- and pH-Responsive Poly(NIPAM-co-HEMA-co-AAm) Nanogel as a Smart Vehicle for Doxorubicin Delivery; Combating Colorectal Cancer. | Gels | 2025 | https://conductscience.org/library/papers/40277662 | PubMed |
| 40244536 | Targeting breast cancer: the promise of phage-based nanomedicines. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40244536 | PubMed |
| 40231513 | Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview. | Curr Top Med Chem | 2025 | https://conductscience.org/library/papers/40231513 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34636282
GET https://conductscience.org/api/papers/v1/34636282/cited_by?page=2